Results for: Narcolepsy

Avadel Pharmaceuticals’ Lumryz, a once-at-bedtime extended-release sodium oxybate, has received FDA approval for treating cataplexy or excessive daytime sleepiness in patients aged seven years and older with narcolepsy. This expansion in the drug’s indication signifies a significant step forward in pediatric narcolepsy treatment, offering a convenient, single-dose option that aligns with the needs of young patients. The approval is anticipated to drive sales for Avadel, bolstering the company’s position within the narcolepsy treatment market.

UBS initiated coverage on Harmony Biosciences Holdings Inc (HRMY) with a Buy rating and a $56 price target, citing strong growth potential for its narcolepsy drug Wakix and a promising pipeline of CNS assets. The firm expects Wakix to achieve $1.2 billion in peak sales, driven by increased narcolepsy diagnosis and the drug’s unique profile in the polypharmacy market.

Jazz Pharmaceuticals and Hikma Pharmaceuticals are facing an antitrust lawsuit alleging they conspired to delay the release of a generic version of Jazz’s narcolepsy drug, Xyrem, resulting in higher prices for health plans. The case will proceed to trial after a judge dismissed some claims. Plaintiffs argue that Jazz violated antitrust laws by making payments to delay generic competition and monopolizing distribution.

In the fourth episode of “Baby Reindeer,” Darrien gives Donny the drug GHB, leaving viewers wondering what it is. GHB, also known as gamma-Hydroxybutyric acid, is prescribed for narcolepsy but can have euphoric effects similar to alcohol and MDMA when abused. Its sedative effects include nausea, dizziness, drowsiness, unconsciousness, and possibly death. Due to its odorless, tasteless, and colorless nature, GHB is often used as a date-rape drug and has a short half-life, making it difficult to detect after an incident.